Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Motif Bio close to hitting home run after latest clinical trial milestone

A home run, by the way, is taking a promising drug candidate from the clinic onto the market
baseball player
It's not quite out of the park, but Motif has almost everything in place to 'go yard'

Q: How often do we see a small, ambitious UK drugs company hit a home run?

A: Rarely

A home run, by the way, is taking a promising drug candidate from the clinic onto the market, something that Motif Bio Plc (NASDAQ:MTFB, LON:MTFB) is close to achieving with its next-generation antibiotic iclaprim.

The drug

Iclaprim is being developed initially for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia (HABP).

It is also expected to target hard-to-treat conditions caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

INSPIRE, a Phase 3 trial designed to study the safety and efficacy of iclaprim in patients with HABP is currently being prepared.

On top of that, Motif is also in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.

One step closer to commercialisation after latest milestone

The company, which also has a listing on the NASDAQ stock exchange in the US, moved a step closer to potentially commercialising iclaprim after the last patient finished their treatment in the REVIVE-2 Phase III trial.

Data from the study - is investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI) – is due out in the fourth quarter of this year.

READ: Iclaprim successfully completes first phase III trial

WATCH: ‘All good news’ from REVIVE-1, says CEO Lumsden

Should the results show that iclaprim scored well against the current gold standard treatment, vancomycin – like it did in the REVIVE-1 phase III trial earlier this year – Motif expects the data gathered from both trials is expected to satisfy the European and US regulatory authorities.

Submission of a new drug application (NDA) for iclaprim as a treatment of ABSSSI is anticipated within the first half of 2018.

Has it got the money for that?

In short: yes it does.

Motif raised US$25.8mln back in June which it said it would use to fund the REVIVE-2 trial thorough to completion.

READ: Motif raises more than originally planned

The money will also allow Motif to file for new drug approval and marketing authorisation for the use of iclaprim in patients with ABSSSI.

Chief executive Graham Lumsden said that Motif is “on track to submit an NDA next year”.

City broker: ‘Positive results will lead to significant re-rate’

“The achievement of this clinical milestone known as last patient out (LPO) follows on from a successful US$25.8m fundraise achieved earlier in the year and brings iclaprim a step closer to potential commercialisation,” said finnCap analyst Alex Pye.

“We continue to expect top-line readout within two or three months, with clinical results for REVIVE-2 possibly being available as early as mid-October.”

Pye added: “We retain our 100p target price and ‘buy’ recommendation as of this morning, expecting positive results to significantly re-rate the shares.”

Shares are up 18% so far in 2017, currently changing hands for just under 30p each.

View full MTFB profile View Profile

Motif Bio Plc Timeline

Big Picture
October 04 2017

Related Articles

picture of drug research
August 22 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use